25 XP   0   0   10

RAPT Therapeutics Inc
Buy, Hold or Sell?

Let's analyze Rapt together

I guess you are interested in RAPT Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of RAPT Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about RAPT Therapeutics Inc

I send you an email if I find something interesting about RAPT Therapeutics Inc.

Quick analysis of Rapt (30 sec.)










What can you expect buying and holding a share of Rapt? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$3.39
Expected worth in 1 year
$1.02
How sure are you?
31.8%

+ What do you gain per year?

Total Gains per Share
$-2.37
Return On Investment
-87.2%

For what price can you sell your share?

Current Price per Share
$2.72
Expected price per share
$0 - $6.86
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

1. Valuation of Rapt (5 min.)




Live pricePrice per Share (EOD)

$2.72

Intrinsic Value Per Share

$-30.64 - $-35.94

Total Value Per Share

$-27.25 - $-32.55

2. Growth of Rapt (5 min.)




Is Rapt growing?

Current yearPrevious yearGrowGrow %
How rich?$130.8m$214.2m-$51.6m-31.8%

How much money is Rapt making?

Current yearPrevious yearGrowGrow %
Making money-$29.5m-$22.1m-$7.3m-24.9%
Net Profit Margin-146.0%-1,386.5%--

How much money comes from the company's main activities?

3. Financial Health of Rapt (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#318 / 966

Most Revenue
#484 / 966

Most Profit
#777 / 966

Most Efficient
#514 / 966
3rd party ad coffee SUPPORTERis ad-free.

What can you expect buying and holding a share of Rapt? (5 min.)

Welcome investor! Rapt's management wants to use your money to grow the business. In return you get a share of Rapt.

What can you expect buying and holding a share of Rapt?

First you should know what it really means to hold a share of Rapt. And how you can make/lose money.

Speculation

The Price per Share of Rapt is $2.72. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Rapt.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Rapt, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $3.39. Based on the TTM, the Book Value Change Per Share is $-0.59 per quarter. Based on the YOY, the Book Value Change Per Share is $0.24 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Rapt.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.79-29.1%-0.77-28.2%-0.64-23.6%-0.53-19.7%-0.54-20.0%
Usd Book Value Change Per Share-0.44-16.3%-0.59-21.8%0.248.7%0.3211.8%0.155.7%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.44-16.3%-0.59-21.8%0.248.7%0.3211.8%0.155.7%
Usd Price Per Share8.98-17.29-20.12-21.16-19.24-
Price to Earnings Ratio-2.84--5.68--7.97--10.54--9.59-
Price-to-Total Gains Ratio-20.25--28.68--12.43--39.37--39.37-
Price to Book Ratio2.65-4.10-3.41-5.22-4.74-
Price-to-Total Gains Ratio-20.25--28.68--12.43--39.37--39.37-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share2.72
Number of shares367
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.590.32
Usd Total Gains Per Share-0.590.32
Gains per Quarter (367 shares)-217.63117.75
Gains per Year (367 shares)-870.54471.01
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-871-8810471461
20-1741-17520942932
30-2612-2623014131403
40-3482-3494018841874
50-4353-4365023552345
60-5223-5236028262816
70-6094-6107032973287
80-6964-6978037683758
90-7835-7849042394229
100-8705-8720047104700

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.022.00.00.0%0.022.00.00.0%
Book Value Change Per Share0.04.00.00.0%3.09.00.025.0%6.014.00.030.0%7.015.00.031.8%7.015.00.031.8%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.022.00.0%0.00.022.00.0%
Total Gains per Share0.04.00.00.0%3.09.00.025.0%6.014.00.030.0%7.015.00.031.8%7.015.00.031.8%
3rd party ad coffee SUPPORTERis ad-free.

Fundamentals of Rapt

About RAPT Therapeutics Inc

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company

Fundamental data was last updated by Penke on 2024-06-19 05:02:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

1.1. Profitability of RAPT Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Rapt earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Rapt to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of RAPT Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-146.0%+146.0%
TTM-146.0%YOY-1,386.5%+1,240.5%
TTM-146.0%5Y-1,054.7%+908.7%
5Y-1,054.7%10Y-958.8%-95.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--168.0%+168.0%
TTM-146.0%-209.9%+63.9%
YOY-1,386.5%-242.3%-1,144.2%
5Y-1,054.7%-401.7%-653.0%
10Y-958.8%-532.2%-426.6%
1.1.2. Return on Assets

Shows how efficient Rapt is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Rapt to the Biotechnology industry mean.
  • -19.6% Return on Assets means that Rapt generated $-0.20 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of RAPT Therapeutics Inc:

  • The MRQ is -19.6%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -16.1%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-19.6%TTM-16.1%-3.4%
TTM-16.1%YOY-9.4%-6.7%
TTM-16.1%5Y-12.1%-4.1%
5Y-12.1%10Y-12.2%+0.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-19.6%-11.9%-7.7%
TTM-16.1%-11.9%-4.2%
YOY-9.4%-11.3%+1.9%
5Y-12.1%-13.5%+1.4%
10Y-12.2%-14.9%+2.7%
1.1.3. Return on Equity

Shows how efficient Rapt is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Rapt to the Biotechnology industry mean.
  • -23.3% Return on Equity means Rapt generated $-0.23 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of RAPT Therapeutics Inc:

  • The MRQ is -23.3%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -18.8%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-23.3%TTM-18.8%-4.5%
TTM-18.8%YOY-10.4%-8.4%
TTM-18.8%5Y-12.7%-6.1%
5Y-12.7%10Y-12.2%-0.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-23.3%-14.2%-9.1%
TTM-18.8%-15.7%-3.1%
YOY-10.4%-14.3%+3.9%
5Y-12.7%-19.2%+6.5%
10Y-12.2%-19.7%+7.5%
3rd party ad coffee SUPPORTERis ad-free.

1.2. Operating Efficiency of RAPT Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Rapt is operating .

  • Measures how much profit Rapt makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Rapt to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of RAPT Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-157.0%+157.0%
TTM-157.0%YOY-1,496.2%+1,339.2%
TTM-157.0%5Y-1,089.0%+931.9%
5Y-1,089.0%10Y-990.0%-99.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--354.6%+354.6%
TTM-157.0%-225.9%+68.9%
YOY-1,496.2%-252.2%-1,244.0%
5Y-1,089.0%-428.3%-660.7%
10Y-990.0%-531.1%-458.9%
1.2.2. Operating Ratio

Measures how efficient Rapt is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of RAPT Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM1.570-1.570
TTM1.570YOY15.596-14.026
TTM1.5705Y11.426-9.855
5Y11.42610Y10.387+1.039
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.004-3.004
TTM1.5703.332-1.762
YOY15.5963.502+12.094
5Y11.4265.271+6.155
10Y10.3876.915+3.472
3rd party ad coffee SUPPORTERis ad-free.

1.3. Liquidity of RAPT Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Rapt is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 7.01 means the company has $7.01 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of RAPT Therapeutics Inc:

  • The MRQ is 7.009. The company is very able to pay all its short-term debts. +2
  • The TTM is 9.110. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ7.009TTM9.110-2.101
TTM9.110YOY14.715-5.606
TTM9.1105Y12.275-3.165
5Y12.27510Y12.624-0.349
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.0093.767+3.242
TTM9.1104.000+5.110
YOY14.7154.905+9.810
5Y12.2755.883+6.392
10Y12.6246.286+6.338
1.3.2. Quick Ratio

Measures if Rapt is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Rapt to the Biotechnology industry mean.
  • A Quick Ratio of 11.24 means the company can pay off $11.24 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of RAPT Therapeutics Inc:

  • The MRQ is 11.236. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 15.348. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ11.236TTM15.348-4.112
TTM15.348YOY26.247-10.898
TTM15.3485Y19.916-4.567
5Y19.91610Y19.538+0.377
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ11.2363.054+8.182
TTM15.3483.506+11.842
YOY26.2474.756+21.491
5Y19.9165.757+14.159
10Y19.5386.338+13.200
3rd party ad coffee SUPPORTERis ad-free.

1.4. Solvency of RAPT Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Rapt assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Rapt to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.16 means that Rapt assets are financed with 16.0% credit (debt) and the remaining percentage (100% - 16.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of RAPT Therapeutics Inc:

  • The MRQ is 0.160. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.136. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.160TTM0.136+0.025
TTM0.136YOY0.094+0.041
TTM0.1365Y0.263-0.128
5Y0.26310Y0.359-0.096
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1600.330-0.170
TTM0.1360.342-0.206
YOY0.0940.287-0.193
5Y0.2630.368-0.105
10Y0.3590.382-0.023
1.4.2. Debt to Equity Ratio

Measures if Rapt is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Rapt to the Biotechnology industry mean.
  • A Debt to Equity ratio of 19.1% means that company has $0.19 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of RAPT Therapeutics Inc:

  • The MRQ is 0.191. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.158. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.191TTM0.158+0.033
TTM0.158YOY0.104+0.054
TTM0.1585Y0.121+0.037
5Y0.12110Y0.114+0.007
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1910.365-0.174
TTM0.1580.415-0.257
YOY0.1040.370-0.266
5Y0.1210.443-0.322
10Y0.1140.476-0.362
3rd party ad coffee SUPPORTERis ad-free.

2. Market Valuation of RAPT Therapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Rapt generates.

  • Above 15 is considered overpriced but always compare Rapt to the Biotechnology industry mean.
  • A PE ratio of -2.84 means the investor is paying $-2.84 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of RAPT Therapeutics Inc:

  • The EOD is -0.861. Based on the earnings, the company is expensive. -2
  • The MRQ is -2.841. Based on the earnings, the company is expensive. -2
  • The TTM is -5.683. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.861MRQ-2.841+1.981
MRQ-2.841TTM-5.683+2.842
TTM-5.683YOY-7.971+2.288
TTM-5.6835Y-10.544+4.861
5Y-10.54410Y-9.585-0.959
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.861-2.341+1.480
MRQ-2.841-2.997+0.156
TTM-5.683-2.882-2.801
YOY-7.971-3.553-4.418
5Y-10.544-6.262-4.282
10Y-9.585-6.288-3.297
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of RAPT Therapeutics Inc:

  • The EOD is -0.966. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -3.189. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -6.298. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.966MRQ-3.189+2.223
MRQ-3.189TTM-6.298+3.109
TTM-6.298YOY-9.769+3.471
TTM-6.2985Y-14.413+8.115
5Y-14.41310Y-13.103-1.310
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.966-2.932+1.966
MRQ-3.189-3.739+0.550
TTM-6.298-3.776-2.522
YOY-9.769-4.917-4.852
5Y-14.413-7.942-6.471
10Y-13.103-8.503-4.600
3rd party ad coffee SUPPORTERis ad-free.
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Rapt is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 2.65 means the investor is paying $2.65 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of RAPT Therapeutics Inc:

  • The EOD is 0.803. Based on the equity, the company is cheap. +2
  • The MRQ is 2.651. Based on the equity, the company is underpriced. +1
  • The TTM is 4.104. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD0.803MRQ2.651-1.848
MRQ2.651TTM4.104-1.453
TTM4.104YOY3.414+0.690
TTM4.1045Y5.217-1.113
5Y5.21710Y4.743+0.474
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.8031.843-1.040
MRQ2.6512.249+0.402
TTM4.1042.301+1.803
YOY3.4142.412+1.002
5Y5.2173.782+1.435
10Y4.7434.212+0.531
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of RAPT Therapeutics Inc.

3.1. Institutions holding RAPT Therapeutics Inc

Institutions are holding 94.106% of the shares of RAPT Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-03-31FMR Inc14.95450.00325219655137626835.8087
2024-03-31Column Group LLC7.680114.9945268062100
2024-03-31Vanguard Group Inc7.14210.0004249285043662921.2345
2024-03-31BlackRock Inc7.08280.00052472153191040.7788
2024-03-31T. Rowe Price Associates, Inc.5.81080.00222028166-1385386-40.5849
2024-03-31Morgan Stanley - Brokerage Accounts5.45890.0014190533485999982.2702
2024-03-31Kingdon Capital Management LLC4.29761.47091500000-431656-22.3464
2024-03-31Perceptive Advisors LLC3.50530.19081223472-916478-42.8271
2024-03-31Geode Capital Management, LLC1.9460.000667921699171.4817
2024-03-31Redmile Group, LLC1.89780.218366239823490854.9505
2024-03-31State Street Corporation1.88920.0003659402-795154-54.6664
2024-03-31Euclidean Capital LLC1.88490.757565789900
2024-03-31Dimensional Fund Advisors, Inc.1.59530.00145568046851814.0323
2024-03-31Alphabet Inc1.54790.19354027000
2024-03-31Cormorant Asset Management, LLC1.42320.195749675000
2024-03-31Two Sigma Investments LLC1.21940.0094256033929621203.8908
2024-03-31Ally Bridge Group (NY) LLC1.20332.09664200004200000
2024-03-31Ardsley Advisory Partners1.15320.51934025004025000
2024-03-31Two Sigma Advisers, LLC0.98130.0071342500278500435.1563
2024-03-31Woodline Partners LP0.92140.026632161312041259.8466
Total 73.59520.689325687206+1091043+4.2%

3.2. Funds holding RAPT Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-04-30Fidelity Growth Compy Commingled Pl O5.72740.0198199906278240.3929
2024-04-30Fidelity Growth Company Fund4.36430.02031523308-14714-0.9567
2024-03-31US Small-Cap Growth II Equity Comp3.94740.0491377775-636914-31.6135
2024-03-31T. Rowe Price New Horizons3.94740.0491377775-636914-31.6135
2024-04-30Vanguard Total Stock Mkt Idx Inv3.21940.00061123686-47580-4.0623
2024-04-30Fidelity Select Biotechnology2.29980.142880270000
2023-12-31UBS: US Equity Small Cap Growth2.1480.76574972100
2024-05-30iShares Russell 2000 ETF1.94660.004767943151480.7635
2024-04-30Xtrackers S&P 500 Swap ETF 1C1.85390.05476470926470920
2024-04-30Fidelity Growth Company K61.44930.021450586171901.4418
2024-04-30Vanguard Institutional Extnd Mkt Idx Tr1.31460.003645885400
2024-04-30Fidelity Series Growth Company1.07470.018937512300
2024-04-30Candriam Eqs L Biotech C USD Cap0.89750.165531326200
2024-03-31Fidelity Small Cap Index0.8360.0098291779-10645-3.5199
2024-03-31T. Rowe Price New Horizons Tr-Z0.81360.0526283959-73686-20.6031
2024-05-30iShares Biotechnology ETF0.62630.0126218617-828-0.3773
2024-03-31Vanguard Strategic Equity Inv0.59990.02232093812093810
2024-05-30iShares Russell 2000 Growth ETF0.53830.00718789500
2023-12-31Empower Small Cap Growth/TimesSquare SP0.52750.56431841001841000
2024-05-31State St Russell Sm/Mid Cp® Indx NL Cl C0.51990.001718147628001.5671
Total 38.65181.985613490857-357746-2.7%

3.3. Insider Transactions

Insiders are holding 1.846% of the shares of RAPT Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-01-05Dirk G BrockstedtSELL89822.78
2023-12-21William HoSELL250021.68
2023-11-28William HoSELL150013.72
2023-10-03William HoSELL250015.77
2023-08-18William HoSELL250018.92
3rd party ad coffee SUPPORTERis ad-free.

4. Summary

4.1. Key Performance Indicators

The key performance indicators of RAPT Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.443-0.593+34%0.238-287%0.321-238%0.154-388%
Book Value Per Share--3.3874.233-20%5.961-43%3.962-15%3.547-5%
Current Ratio--7.0099.110-23%14.715-52%12.275-43%12.624-44%
Debt To Asset Ratio--0.1600.136+18%0.094+70%0.263-39%0.359-55%
Debt To Equity Ratio--0.1910.158+21%0.104+83%0.121+58%0.114+68%
Dividend Per Share----0%-0%-0%-0%
Eps---0.790-0.768-3%-0.641-19%-0.535-32%-0.545-31%
Free Cash Flow Per Share---0.704-0.690-2%-0.523-26%-0.451-36%-0.436-38%
Free Cash Flow To Equity Per Share---0.470-0.623+32%0.404-216%0.120-491%0.122-486%
Gross Profit Margin--1.0101.005+1%1.000+1%1.001+1%1.001+1%
Intrinsic Value_10Y_max---35.940--------
Intrinsic Value_10Y_min---30.639--------
Intrinsic Value_1Y_max---2.425--------
Intrinsic Value_1Y_min---2.382--------
Intrinsic Value_3Y_max---8.183--------
Intrinsic Value_3Y_min---7.794--------
Intrinsic Value_5Y_max---15.022--------
Intrinsic Value_5Y_min---13.866--------
Market Cap94937520.000-265%346855777.700663738205.298-48%721466090.763-52%754538190.962-54%685943809.965-49%
Net Profit Margin----1.4600%-13.8650%-10.5470%-9.5880%
Operating Margin----1.5700%-14.9620%-10.8900%-9.9000%
Operating Ratio---1.570-100%15.596-100%11.426-100%10.387-100%
Pb Ratio0.803-230%2.6514.104-35%3.414-22%5.217-49%4.743-44%
Pe Ratio-0.861+70%-2.841-5.683+100%-7.971+181%-10.544+271%-9.585+237%
Price Per Share2.720-230%8.98017.288-48%20.115-55%21.161-58%19.237-53%
Price To Free Cash Flow Ratio-0.966+70%-3.189-6.298+97%-9.769+206%-14.413+352%-13.103+311%
Price To Total Gains Ratio-6.135+70%-20.254-28.678+42%-12.433-39%-39.373+94%-39.373+94%
Quick Ratio--11.23615.348-27%26.247-57%19.916-44%19.538-42%
Return On Assets---0.196-0.161-18%-0.094-52%-0.121-38%-0.122-38%
Return On Equity---0.233-0.188-19%-0.104-55%-0.127-45%-0.122-48%
Total Gains Per Share---0.443-0.593+34%0.238-287%0.321-238%0.154-388%
Usd Book Value--130835000.000162586750.000-20%214268750.000-39%142491300.000-8%127639681.818+3%
Usd Book Value Change Per Share---0.443-0.593+34%0.238-287%0.321-238%0.154-388%
Usd Book Value Per Share--3.3874.233-20%5.961-43%3.962-15%3.547-5%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.790-0.768-3%-0.641-19%-0.535-32%-0.545-31%
Usd Free Cash Flow---27189000.000-26500250.000-3%-18812500.000-31%-16347850.000-40%-15767045.455-42%
Usd Free Cash Flow Per Share---0.704-0.690-2%-0.523-26%-0.451-36%-0.436-38%
Usd Free Cash Flow To Equity Per Share---0.470-0.623+32%0.404-216%0.120-491%0.122-486%
Usd Market Cap94937520.000-265%346855777.700663738205.298-48%721466090.763-52%754538190.962-54%685943809.965-49%
Usd Price Per Share2.720-230%8.98017.288-48%20.115-55%21.161-58%19.237-53%
Usd Profit---30521000.000-29512000.000-3%-22175500.000-27%-19140900.000-37%-18247090.909-40%
Usd Revenue---1322000.000-100%381750.000-100%815550.000-100%741409.091-100%
Usd Total Gains Per Share---0.443-0.593+34%0.238-287%0.321-238%0.154-388%
 EOD+3 -5MRQTTM+11 -21YOY+4 -285Y+6 -2610Y+7 -25

4.2. Fundamental Score

Let's check the fundamental score of RAPT Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.861
Price to Book Ratio (EOD)Between0-10.803
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than111.236
Current Ratio (MRQ)Greater than17.009
Debt to Asset Ratio (MRQ)Less than10.160
Debt to Equity Ratio (MRQ)Less than10.191
Return on Equity (MRQ)Greater than0.15-0.233
Return on Assets (MRQ)Greater than0.05-0.196
Total5/10 (50.0%)

4.3. Technical Score

Let's check the technical score of RAPT Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5024.404
Ma 20Greater thanMa 503.317
Ma 50Greater thanMa 1004.768
Ma 100Greater thanMa 2007.699
OpenGreater thanClose2.790
Total1/5 (20.0%)



Latest Balance Sheet

Balance Sheet of 2024-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets155,818
Total Liabilities24,983
Total Stockholder Equity130,835
 As reported
Total Liabilities 24,983
Total Stockholder Equity+ 130,835
Total Assets = 155,818

Assets

Total Assets155,818
Total Current Assets148,360
Long-term Assets7,458
Total Current Assets
Cash And Cash Equivalents 45,317
Short-term Investments 96,262
Other Current Assets 6,781
Total Current Assets  (as reported)148,360
Total Current Assets  (calculated)148,360
+/-0
Long-term Assets
Property Plant Equipment 7,011
Long-term Assets Other 447
Long-term Assets  (as reported)7,458
Long-term Assets  (calculated)7,458
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities21,168
Long-term Liabilities3,815
Total Stockholder Equity130,835
Total Current Liabilities
Short-term Debt 2,508
Accounts payable 6,771
Other Current Liabilities 11,889
Total Current Liabilities  (as reported)21,168
Total Current Liabilities  (calculated)21,168
+/-0
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt3,815
Long-term Liabilities  (as reported)3,815
Long-term Liabilities  (calculated)3,815
+/-0
Total Stockholder Equity
Common Stock3
Retained Earnings -515,203
Accumulated Other Comprehensive Income -10
Other Stockholders Equity 646,045
Total Stockholder Equity (as reported)130,835
Total Stockholder Equity (calculated)130,835
+/-0
Other
Capital Stock3
Cash and Short Term Investments 141,579
Common Stock Shares Outstanding 38,625
Liabilities and Stockholders Equity 155,818
Net Debt -38,994
Net Invested Capital 130,835
Net Working Capital 127,192
Property Plant and Equipment Gross 16,690
Short Long Term Debt Total 6,323



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-31
> Total Assets 
0
0
0
69,610
67,860
68,109
58,369
84,602
150,889
139,676
128,970
118,969
105,924
231,081
217,462
198,636
187,548
221,996
209,489
266,209
248,326
220,756
199,721
173,329
155,818
155,818173,329199,721220,756248,326266,209209,489221,996187,548198,636217,462231,081105,924118,969128,970139,676150,88984,60258,36968,10967,86069,610000
   > Total Current Assets 
0
0
0
65,062
63,224
62,056
51,224
80,506
146,894
136,077
125,508
115,598
102,606
227,955
214,495
192,973
175,664
209,929
197,894
252,694
234,587
207,417
187,138
161,782
148,360
148,360161,782187,138207,417234,587252,694197,894209,929175,664192,973214,495227,955102,606115,598125,508136,077146,89480,50651,22462,05663,22465,062000
       Cash And Cash Equivalents 
0
0
0
63,798
61,758
59,862
48,310
77,383
91,529
28,957
20,229
24,918
24,720
86,220
59,999
24,027
32,418
57,203
27,706
38,946
45,768
50,164
54,135
47,478
45,317
45,31747,47854,13550,16445,76838,94627,70657,20332,41824,02759,99986,22024,72024,91820,22928,95791,52977,38348,31059,86261,75863,798000
       Short-term Investments 
0
0
0
0
0
0
0
0
46,670
103,993
102,557
86,592
73,686
137,084
150,787
165,627
140,590
150,138
167,730
210,122
185,861
154,834
130,642
111,384
96,262
96,262111,384130,642154,834185,861210,122167,730150,138140,590165,627150,787137,08473,68686,592102,557103,99346,67000000000
       Net Receivables 
0
0
0
0
0
0
0
0
5,010
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000005,01000000000
       Other Current Assets 
0
0
0
1,264
1,466
2,194
2,914
3,123
3,685
3,127
2,722
4,088
4,200
4,651
3,709
3,319
2,656
2,588
2,458
3,626
2,958
2,419
2,361
2,920
6,781
6,7812,9202,3612,4192,9583,6262,4582,5882,6563,3193,7094,6514,2004,0882,7223,1273,6853,1232,9142,1941,4661,264000
   > Long-term Assets 
0
0
0
4,548
4,636
6,053
7,145
4,096
3,995
3,599
3,462
3,371
3,318
3,126
2,967
5,663
11,884
12,067
11,595
13,515
13,739
13,339
12,583
11,547
7,458
7,45811,54712,58313,33913,73913,51511,59512,06711,8845,6632,9673,1263,3183,3713,4623,5993,9954,0967,1456,0534,6364,548000
       Property Plant Equipment 
0
0
0
4,159
4,247
4,277
4,002
3,707
3,606
3,210
3,073
2,982
2,929
2,737
2,578
2,741
8,951
8,976
8,524
9,479
9,525
9,066
8,376
7,676
7,011
7,0117,6768,3769,0669,5259,4798,5248,9768,9512,7412,5782,7372,9292,9823,0733,2103,6063,7074,0024,2774,2474,159000
       Other Assets 
0
0
0
0
389
1,776
3,143
389
389
389
389
389
389
389
389
2,922
2,933
3,091
3,071
4,036
0
4,273
0
0
0
0004,27304,0363,0713,0912,9332,9223893893893893893893893893,1431,7763890000
> Total Liabilities 
0
0
0
5,612
173,611
8,103
183,166
11,481
18,960
17,065
18,923
14,790
14,283
13,502
15,589
12,256
19,713
19,863
20,183
21,043
27,856
21,079
26,921
26,294
24,983
24,98326,29426,92121,07927,85621,04320,18319,86319,71312,25615,58913,50214,28314,79018,92317,06518,96011,481183,1668,103173,6115,612000
   > Total Current Liabilities 
0
0
0
4,643
3,471
5,895
5,457
9,256
13,442
13,080
15,591
11,742
11,143
10,394
12,695
9,595
12,360
13,146
13,867
14,224
21,608
15,414
21,849
21,836
21,168
21,16821,83621,84915,41421,60814,22413,86713,14612,3609,59512,69510,39411,14311,74215,59113,08013,4429,2565,4575,8953,4714,643000
       Short-term Debt 
0
0
0
0
0
0
0
3,642
3,832
4,256
5,669
4,935
4,539
5,068
6,845
6,326
1,481
1,503
1,551
2,171
2,278
2,333
2,390
2,448
2,508
2,5082,4482,3902,3332,2782,1711,5511,5031,4816,3266,8455,0684,5394,9355,6694,2563,8323,6420000000
       Accounts payable 
0
0
0
1,771
1,320
2,604
1,590
1,143
3,409
2,381
4,405
2,383
3,131
2,714
4,017
1,999
1,936
4,097
4,043
3,365
8,941
2,690
5,297
5,176
6,771
6,7715,1765,2972,6908,9413,3654,0434,0971,9361,9994,0172,7143,1312,3834,4052,3813,4091,1431,5902,6041,3201,771000
       Other Current Liabilities 
0
0
0
2,872
2,151
3,291
3,867
471
436
430
389
328
338
329
295
254
8,298
7,546
8,273
8,688
10,389
96
53
14,212
11,889
11,88914,212539610,3898,6888,2737,5468,2982542953293383283894304364713,8673,2912,1512,872000
   > Long-term Liabilities 
0
0
0
969
170,140
2,208
177,709
2,225
5,518
3,985
3,332
3,048
3,140
3,108
2,894
2,661
7,353
6,717
6,316
6,819
6,248
5,665
5,072
4,458
3,815
3,8154,4585,0725,6656,2486,8196,3166,7177,3532,6612,8943,1083,1403,0483,3323,9855,5182,225177,7092,208170,140969000
       Other Liabilities 
0
0
0
0
2,082
2,208
2,219
2,225
5,518
3,985
3,332
3,048
3,140
3,108
2,894
2,661
241
0
0
0
0
0
0
0
0
000000002412,6612,8943,1083,1403,0483,3323,9855,5182,2252,2192,2082,0820000
       Deferred Long Term Liability 
0
0
0
0
0
0
2,800
0
0
0
0
3,048
3,140
3,108
2,894
2,661
241
0
0
0
0
0
0
0
0
000000002412,6612,8943,1083,1403,04800002,800000000
> Total Stockholder Equity
-62,405
0
0
63,998
-105,751
60,006
-124,797
73,121
131,929
122,611
110,047
104,179
91,641
217,579
201,873
186,380
167,835
202,133
189,306
245,166
220,470
199,677
172,800
147,035
130,835
130,835147,035172,800199,677220,470245,166189,306202,133167,835186,380201,873217,57991,641104,179110,047122,611131,92973,121-124,79760,006-105,75163,99800-62,405
   Common Stock
0
0
0
2
1
2
1
2
2
2
2
2
2
3
3
3
3
3
3
3
3
3
3
3
3
3333333333332222221212000
   Retained Earnings Total Equity000-422,435-397,155-367,884-344,933-323,698-304,514-284,046-266,117-247,466-231,356-214,84200000000000
   Accumulated Other Comprehensive Income 
0
0
0
-4
-4
-2
13
20
7
177
74
-177
-189
-137
45
-206
-1,117
-745
-453
-26
339
-180
-121
103
-10
-10103-121-180339-26-453-745-1,117-20645-137-189-1777417772013-2-4-4000
   Capital Surplus 
0
0
0
0
22,884
23,265
23,923
235,049
307,009
0
0
319,196
323,184
465,179
467,942
470,629
473,463
526,573
534,689
613,073
617,283
622,289
0
0
0
000622,289617,283613,073534,689526,573473,463470,629467,942465,179323,184319,19600307,009235,04923,92323,26522,8840000
   Treasury Stock0000000000000000000000000
   Other Stockholders Equity 
0
0
0
187,918
27,689
204,383
-151,567
241,128
313,274
316,688
319,018
104,354
323,184
465,179
467,942
470,629
473,463
526,573
534,689
613,073
617,283
622,289
626,724
631,611
646,045
646,045631,611626,724622,289617,283613,073534,689526,573473,463470,629467,942465,179323,184104,354319,018316,688313,274241,128-151,567204,38327,689187,918000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-3,551
Gross Profit-3,551-3,551
 
Operating Income (+$)
Gross Profit-3,551
Operating Expense-123,511
Operating Income-127,062-127,062
 
Operating Expense (+$)
Research Development101,002
Selling General Administrative26,060
Selling And Marketing Expenses3,551
Operating Expense123,511130,613
 
Net Interest Income (+$)
Interest Income0
Interest Expense-0
Other Finance Cost-0
Net Interest Income0
 
Pretax Income (+$)
Operating Income-127,062
Net Interest Income0
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-116,798-137,326
EBIT - interestExpense = -127,062
-116,798
-116,798
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-127,062-116,798
Earnings Before Interest and Taxes (EBITDA)-123,511
 
After tax Income (+$)
Income Before Tax-116,798
Tax Provision-0
Net Income From Continuing Ops-108,873-116,798
Net Income-116,798
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses127,062
Total Other Income/Expenses Net10,2640
 

Technical Analysis of Rapt
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Rapt. The general trend of Rapt is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Rapt's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of RAPT Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 4.6 < 4.83 < 6.86.

The bearish price targets are: .

Tweet this
RAPT Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of RAPT Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

RAPT Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of RAPT Therapeutics Inc. The current macd is -0.53573982.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Rapt price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Rapt. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Rapt price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
RAPT Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartRAPT Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of RAPT Therapeutics Inc. The current adx is 40.83.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Rapt shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
RAPT Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of RAPT Therapeutics Inc. The current sar is 3.11.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
RAPT Therapeutics Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of RAPT Therapeutics Inc. The current rsi is 24.40. The current phase is Oversold in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Oversold in bear market: Short-term excessive selling, potential for relief rally. Be cautious, consider taking short-term long positions. +1
  • Trending down: The RSI is trending down. -1
RAPT Therapeutics Inc Daily Relative Strength Index (RSI) ChartRAPT Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of RAPT Therapeutics Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Rapt price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
RAPT Therapeutics Inc Daily Stochastic Oscillator ChartRAPT Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of RAPT Therapeutics Inc. The current cci is -113.41310609.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
RAPT Therapeutics Inc Daily Commodity Channel Index (CCI) ChartRAPT Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of RAPT Therapeutics Inc. The current cmo is -54.20410333.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
RAPT Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartRAPT Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of RAPT Therapeutics Inc. The current willr is -95.65217391.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
RAPT Therapeutics Inc Daily Williams %R ChartRAPT Therapeutics Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of RAPT Therapeutics Inc.

RAPT Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of RAPT Therapeutics Inc. The current atr is 0.27415585.

RAPT Therapeutics Inc Daily Average True Range (ATR) ChartRAPT Therapeutics Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of RAPT Therapeutics Inc. The current obv is -10,675,736.

RAPT Therapeutics Inc Daily On-Balance Volume (OBV) ChartRAPT Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of RAPT Therapeutics Inc. The current mfi is 37.97.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
RAPT Therapeutics Inc Daily Money Flow Index (MFI) ChartRAPT Therapeutics Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for RAPT Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-14CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-20DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-21ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-12WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-13RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-25WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-28WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-04WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-05CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-10CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-04-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-16WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-18CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-25CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-29STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-05-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-05-02CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-05-03CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-05-07STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-05-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-05-09MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-05-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-21RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-05-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-05-30STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-06-05RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-06STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-06-07CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-06-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-06-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-14BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-06-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-06-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-25STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-06-26MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-06-28STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-07-01SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-07-02SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside

6.3. Candlestick Patterns

RAPT Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of RAPT Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5024.404
Ma 20Greater thanMa 503.317
Ma 50Greater thanMa 1004.768
Ma 100Greater thanMa 2007.699
OpenGreater thanClose2.790
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Rapt with someone you think should read this too:
  • Are you bullish or bearish on Rapt? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Rapt? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about RAPT Therapeutics Inc

I send you an email if I find something interesting about RAPT Therapeutics Inc.


Stay informed about RAPT Therapeutics Inc.

Receive notifications about RAPT Therapeutics Inc in your mailbox!